The role of a ceRNA regulatory network based on lncRNA MALAT1 site in cancer progression

Su, Kai; Wang, Nannan; Shao, Qianqian; Liu, Hao; Bao, Zhao; Ma, Sai

doi:10.1016/j.biopha.2021.111389

Cited by 81 publications

(71 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In multiple myeloma, MALAT1 regulates proliferation and adhesion of multiple myeloma cells via hsa-miR-181-5p/Hippo-YAP axis. Moreover, a study by Gu et al reported that MALAT1 is overexpressed in multiple myeloma, and regulates cell proliferation, apoptosis, and cell-cycle through the ceRNA network involving the hsa-miR-509-5p/Foxp1 pathway [ 39 ]. Very recently, MALAT1 was reported to directly bind to hsa-miR-150, releasing their suppressive effect on the target mRNAs, promoting cell proliferation and inhibiting apoptosis [ 40 , 41 ].…”

Section: Discussionmentioning

confidence: 99%

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

Fernandes

Marques

Teixeira

et al. 2021

IJMS

View full text Add to dashboard Cite

Research has been focusing on identifying novel biomarkers to better stratify non-Hodgkin lymphoma patients based on prognosis. Studies have demonstrated that lncRNAs act as miRNA sponges, creating ceRNA networks to regulate mRNA expression, and its deregulation is associated with lymphoma development. This study aimed to identify novel circulating prognostic biomarkers based on miRNA/lncRNA-associated ceRNA network for NHL. Herein, bioinformatic analysis was performed to construct ceRNA networks for hsa-miR-150-5p and hsa-miR335-5p. Then, the prognostic value of the miRNA–lncRNA pairs’ plasma levels was assessed in a cohort of 113 NHL patients. Bioinformatic analysis identified MALAT1 and NEAT1 as hsa-miR-150-5p and has-miR-335-5p sponges, respectively. Plasma hsa-miR-150-5p/MALAT1 and hsa-miR335-5p/NEAT1 levels were significantly associated with more aggressive and advanced disease. The overall survival and progression-free survival analysis indicated that hsa-miR-150-5p/MALAT1 and hsa-miR335-5p/NEAT1 pairs’ plasma levels were remarkably associated with NHL patients’ prognosis, being independent prognostic factors in a multivariate Cox analysis. Low levels of hsa-miR-150-5p and hsa-miR-335-5p combined with high levels of the respective lncRNA pair were associated with poor prognosis of NHL patients. Overall, the analysis of ceRNA network expression levels may be a useful prognostic biomarker for NHL patients and could identify patients who could benefit from more intensive treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

Fernandes

Marques

Teixeira

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…As one of the most well-known lncRNAs, MALAT1 is located on human chromosome 11q13, originally found in non-small cell lung cancer, and highly expressed in a variety of tumors [ 24 ]. It is considered as a biomarker of multiple tumors which can promote tumor cell proliferation, metastasis and invasion.…”

Section: The Research Status Of Lncrnas Related To Osteogenic Differe...mentioning

confidence: 99%

The management of bone defect using long non-coding RNA as a potential biomarker for regulating the osteogenic differentiation process

Liu

Zheng

et al. 2022

Mol Biol Rep

View full text Add to dashboard Cite

Tissue engineered bone brings hope to the treatment of bone defects, and the osteogenic differentiation of stem cells is the key link. Inducing osteogenic differentiation of stem cells may be a potential approach to promote bone regeneration. In recent years, lncRNA has been studied in the field increasingly, which is believed can regulate cell cycle, proliferation, metastasis, differentiation and immunity, participating in a variety of physiology and pathology processes. At present, it has been confirmed that certain lncRNAs regulate the osteogenesis of stem cells and take part in mediating signaling pathways including Wnt/β-catenin, MAPK, TGF-β/BMP, and Notch pathways. Here, we provided an overview of lncRNA, reviewed its researches in the osteogenic differentiation of stem cells, emphasized the importance of lncRNA in bone regeneration, and focused on the roles of lncRNA in signaling pathways, in order to make adequate preparations for applying lncRNA to bone tissue Engineering, letting it regulate the osteogenic differentiation of stem cells for bone regeneration.

show abstract

“…It is common knowledge that miRNAs mainly inhibit the expression of target genes by binding to mRNAs. ceRNAs can competitively bind to and inactivate miRNAs through MREs, thereby affecting the mRNA level of target genes [ 116 – 118 ]. Multiple studies have shown that lncRNAs, as ceRNAs, play an important role in malignant tumours and other diseases.…”

Section: Snhg4 Involved In Cerna Regulationmentioning

confidence: 99%

Long noncoding RNA SNHG4: a novel target in human diseases

Chu

Zheng

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Recently, long noncoding RNAs (lncRNAs) have attracted great attention from researchers. LncRNAs are non-protein-coding RNAs of more than 200 nucleotides in length. Multiple studies have been published on the relationship between lncRNA expression and the progression of human diseases. LncRNA small nucleolar RNA host gene 4 (SNHG4), a member of the lncRNA SNHG family, is abnormally expressed in a variety of human diseases, including gastric cancer, renal cell carcinoma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, osteosarcoma, cervical cancer, liver cancer, lung cancer, non-small-cell lung cancer, neonatal pneumonia, diabetic retinopathy, neuropathic pain, acute cerebral infarction, acute myeloid leukaemia, and endometriosis. In this paper, the structure of SNHG4 is first introduced, and then studies in humans, animal models and cells are summarized to highlight the expression and function of SNHG4 in the above diseases. In addition, the specific mechanism of SNHG4 as a competing endogenous RNA (ceRNA) is discussed. The findings indicate that SNHG4 can be used as a biomarker for disease prognosis evaluation and as a potential target for disease diagnosis and treatment.

show abstract

The role of a ceRNA regulatory network based on lncRNA MALAT1 site in cancer progression

Cited by 81 publications

References 63 publications

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

The management of bone defect using long non-coding RNA as a potential biomarker for regulating the osteogenic differentiation process

Long noncoding RNA SNHG4: a novel target in human diseases

Contact Info

Product

Resources

About